Properdin: a tightly regulated critical inflammatory modulator

被引:69
作者
Blatt, Adam Z. [1 ]
Pathan, Sabina [1 ]
Ferreira, Viviana P. [1 ]
机构
[1] Univ Toledo, Coll Med, Dept Med Microbiol & Immunol, 2801 W Bancroft St, Toledo, OH 43606 USA
基金
美国国家卫生研究院;
关键词
complement; factor H; inflammation; properdin; COMPLEMENT FACTOR-H; PLATELET-LEUKOCYTE INTERACTIONS; HEMOLYTIC-UREMIC SYNDROME; SURFACE-ADHERENT PLATELETS; MEMBRANE ATTACK COMPLEX; HEPARIN-BINDING DOMAIN; C-TERMINAL DOMAINS; X-RAY-SCATTERING; ALTERNATIVE-PATHWAY; P-SELECTIN;
D O I
10.1111/imr.12466
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The complement alternative pathway is a powerful arm of the innate immune system that enhances diverse inflammatory responses in the human host. Key to the effects of the alternative pathway is properdin, a serum glycoprotein that can both initiate and positively regulate alternative pathway activity. Properdin is produced by many different leukocyte subsets and circulates as cyclic oligomers of monomeric subunits. While the formation of non-physiological aggregates in purified properdin preparations and the presence of potential properdin inhibitors in serum have complicated studies of its function, properdin has, regardless, emerged as a key player in various inflammatory disease models. Here, we review basic properdin biology, emphasizing the major hurdles that have complicated the interpretation of results from properdin-centered studies. In addition, we elaborate on an emerging role for properdin in thromboinflammation and discuss the potential utility of properdin inhibitors as long-term therapeutic options to treat diseases marked by increased formation of platelet/granulocyte aggregates. Finally, we describe the interplay between properdin and the alternative pathway negative regulator, Factor H, and how aiming to understand these interactions can provide scientists with the most effective ways to manipulate alternative pathway activation in complex systems.
引用
收藏
页码:172 / 190
页数:19
相关论文
共 212 条
  • [91] Atypical Hemolytic Uremic Syndrome
    Kavanagh, David
    Goodship, Tim H.
    Richards, Anna
    [J]. SEMINARS IN NEPHROLOGY, 2013, 33 (06) : 508 - 530
  • [92] The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis
    Kemper, Claudia
    Mitchell, Lynne M.
    Zhang, Lijuan
    Hourcade, Dennis E.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (26) : 9023 - 9028
  • [93] Properdin: Emerging Roles of a Pattern-Recognition Molecule
    Kemper, Claudia
    Atkinson, John P.
    Hourcade, Dennis E.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 28, 2010, 28 : 131 - 155
  • [94] Bivalent and co-operative binding of complement Factor H to heparan sulfate and heparins
    Khan, Sanaullah
    Nan, Ruodan
    Gor, Jayesh
    Mulloy, Barbara
    Perkins, Stephen J.
    [J]. BIOCHEMICAL JOURNAL, 2012, 444 : 417 - 428
  • [95] Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury
    Kimura, Yuko
    Zhou, Lin
    Miwa, Takashi
    Song, Wen-Chao
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (10) : 3545 - 3554
  • [96] The role of the anaphylatoxins in health and disease
    Klos, Andreas
    Tenner, Andrea J.
    Johswich, Kay-Ole
    Ager, Rahasson R.
    Reis, Edimara S.
    Koehl, Joerg
    [J]. MOLECULAR IMMUNOLOGY, 2009, 46 (14) : 2753 - 2766
  • [97] Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H
    Kuhn, S
    Zipfel, PF
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (10) : 2383 - 2387
  • [98] KUHN S, 1995, J IMMUNOL, V155, P5663
  • [99] Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation
    Lappegård, KT
    Fung, M
    Bergseth, G
    Riesenfeld, J
    Lambris, JD
    Videm, V
    Mollnes, TE
    [J]. ANNALS OF THORACIC SURGERY, 2004, 77 (03) : 932 - 941
  • [100] Mutations of Factor H Impair Regulation of Surface-bound C3b by Three Mechanisms in Atypical Hemolytic Uremic Syndrome
    Lehtinen, Markus J.
    Rops, Angelique L.
    Isenman, David E.
    van der Vlag, Johan
    Jokiranta, T. Sakari
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (23) : 15650 - 15658